No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 620 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR ESMO Publishes First Guidance on the Safe Use of Large Language... October 18, 2025 5 ways cancer can impact sexual wellbeing May 17, 2023 How Does Ovarian Cancer Form? A New Study Points to MicroRNA July 30, 2020 De qué manera el seguimiento de los síntomas mejora la atención... May 6, 2021 Load more HOT NEWS EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical... Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with... COVID-19 Pandemic Halts Cancer Care and Damages Oncologists’ Wellbeing [ESMO Press... Airbrushed Magazines Hurt the Body Image of Young Women — Here’s...
